Ardelyx, Inc. key statistics and ratios
In fiscal 2025, Ardelyx, Inc. had return on equity of -36.2%, an operating margin of -10.1%, debt equal to 121.5% of equity and a current ratio of 4.31. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.
Financial ratios
| Fiscal year | 2012Dec 2012 | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | — | — | — | 100.0% | 80.0% | 82.1% | 88.6% | 98.1% | 90.1% | 92.1% | 85.7% | 84.8% | 90.3% | 94.4% |
| Operating margin | −162.8% | −9.9% | −4.9% | −122.3% | −155.0% | <−999% | <−999% | <−999% | <−999% | −122.2% | −50.8% | −8.4% | −10.1% | −7.9% |
| Net margin | −180.9% | −22.7% | −10.2% | −123.3% | −153.2% | <−999% | <−999% | <−999% | <−999% | −128.9% | −53.1% | −11.7% | −15.1% | −12.4% |
| Free-cash-flow margin | 403.9% | 5.3% | 36.5% | −313.4% | −160.8% | <−999% | <−999% | <−999% | <−999% | −134.4% | −72.4% | −13.7% | −10.8% | −4.0% |
| Return on equity | — | — | — | −34.9% | −51.8% | −71.6% | −62.8% | −60.3% | −151.6% | −74.3% | −49.8% | −23.0% | −36.2% | −35.3% |
| Return on assets | — | −15.3% | −4.1% | −25.7% | −46.8% | −53.5% | −42.9% | −40.9% | −90.0% | −39.5% | −27.1% | −10.7% | −13.1% | −10.3% |
| Asset turnover | — | 0.67 | 0.40 | 0.21 | 0.31 | 0.02 | 0.02 | 0.03 | 0.06 | 0.31 | 0.51 | 0.91 | 0.87 | 0.84 |
| Current ratio | — | 2.44 | 5.16 | 14.51 | 5.00 | 9.95 | 11.34 | 6.85 | 2.53 | 2.34 | 4.88 | 4.58 | 4.31 | 3.34 |
| Debt to equity | — | — | 0.0% | 0.0% | 0.0% | 44.9% | 27.8% | 41.6% | 40.0% | 29.4% | 31.5% | 87.1% | 121.5% | 169.0% |
| Interest cover (operating income ÷ interest) | — | — | — | — | — | n/m | n/m | n/m | n/m | n/m | n/m | n/m | n/m | n/m |
| R&D as % of revenue | 188.2% | 97.1% | 81.9% | 166.0% | 179.7% | >999% | >999% | 859.2% | 902.6% | 67.5% | 28.6% | 15.7% | 17.6% | 19.3% |
| SG&A as % of revenue | — | — | — | — | — | — | — | — | 716.1% | 146.9% | 108.0% | 77.5% | 82.8% | 82.9% |
| Capital spending as % of revenue | 2.4% | 1.0% | 5.9% | 14.4% | 5.6% | 11.9% | 6.2% | 4.3% | 18.5% | 0.1% | 0.3% | 0.3% | 0.4% | 0.1% |
| Dividends and buybacks ÷ free cash flow | 0.1% | 0.1% | 0.0% | — | — | — | — | — | — | — | — | — | — | — |
| Quarter | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Gross margin | 84.0% | 84.3% | 83.4% | 87.3% | 96.4% | 91.3% | 94.9% | 95.2% |
| Operating margin | 2.3% | 7.0% | −49.0% | −14.7% | 4.2% | 4.1% | −34.7% | −10.3% |
| Net margin | −0.8% | 4.0% | −55.5% | −19.5% | −0.9% | −0.3% | −39.8% | −13.8% |
| Free-cash-flow margin | 0.4% | 7.9% | −52.3% | −26.6% | 0.2% | 16.4% | −34.2% | −5.3% |
| Current ratio | 4.03 | 4.58 | 4.12 | 4.30 | 4.41 | 4.31 | 3.49 | 3.34 |
| Debt to equity | 63.6% | 87.1% | 103.9% | 144.4% | 131.0% | 121.5% | 136.9% | 169.0% |
| R&D as % of revenue | 15.6% | 11.8% | 20.2% | 16.0% | 16.4% | 18.3% | 21.4% | 21.6% |
| SG&A as % of revenue | 66.1% | 65.5% | 112.3% | 86.0% | 75.8% | 69.0% | 108.3% | 83.9% |
Financial health
- Short-term assets cover short-term liabilities $442m of assets due within a year against $132m of liabilities due within a year.
- Short-term assets cover long-term liabilities $442m short-term assets against $295m of longer-dated liabilities.
- More cash than debt $97m of cash against $252m of debt.
- Debt below 40% of shareholders' equity Debt is 169% of equity.
- Debt burden no higher than five years ago Debt to equity moved from 39% to 169% over five years.
- A year's operating cash flow covers at least 20% of debt −$17m of operating cash flow against $252m of debt.
- Operating profit covers interest at least five times over Operating income of −$35m against $22m of interest.
Moat
Weak moat
How hard Ardelyx's competitive advantage looks for rivals to wear away, judged from 9 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.
- Returns on capital 0 / 20
Cash operating profit has been a median -22.4% of total assets over 5 years.
- Pricing power 18 / 20
Gross margin has been a median 91.1%, moving by 3.8 percentage points (standard deviation) across 7 years.
- Durability 10 / 20
Operating margin has been a median -63.3%; its worst year was -2531.4%.
- Cash conversion 1 / 20
Free cash flow was positive in 1 of 9 years, at a median -85.5% of revenue.
- Discipline 0 / 20
The diluted share count rose 159.4% over five years; stock-based pay has been a median 12.3% of revenue.
AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (29 before it).
Compare with peers
- Cormedix Inc. statistics
- Arcutis Biotherapeutics, Inc. statistics
- Krystal Biotech, Inc. statistics
- Novavax Inc statistics
- Meiragtx Holdings plc statistics
Head to head: ARDX vs CRMDARDX vs ARQTARDX vs KRYS
More: Biotechnology stocks compared, Health Care sector, rankings of US companies